I-MAB (NASDAQ: IMAB)
$1.62
-0.0100 ( -0.61% ) 20.2K
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Market Data
Open
$1.62
Previous close
$1.63
Volume
20.2K
Market cap
$130.83M
Day range
$1.62 - $1.65
52 week range
$1.16 - $3.17
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 1 | Feb 06, 2024 |
6-k | Quarterly Reports | 3 | Oct 10, 2023 |
6-k | Quarterly Reports | 1 | Sep 22, 2023 |
6-k | Quarterly Reports | 3 | Aug 17, 2023 |